<DOC>
	<DOCNO>NCT01986933</DOCNO>
	<brief_summary>To assess safety , tolerability efficacy CIM331 , compare placebo , atopic dermatitis patient inadequately control intolerant topical therapy</brief_summary>
	<brief_title>A Phase 2 Study CIM331 Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>≥18 ≤65 year age time consent . Patients Atopic Dermatitis Pruritus visual analogue scale ( VAS ) ≥50 mm screen baseline visit Eczema Area Severity Index ( EASI ) ≥10 screen baseline visit static Investigator 's Global Assessment ( sIGA ) score ≥3 baseline visit Serological evidence hepatitis B virus hepatitis C virus infection Known human immunodeficiency virus infection Ongoing treatment specific nonspecific hyposensitization therapy AD Treatment mild moderately potent topical corticosteroid ( TCS ) within 1 week prior randomization History infection include skin infection require treatment oral intravenous ( IV ) antibiotic , antiviral , antifungal within 1 week prior randomization . Evidence tuberculosis ( TB ) infection define positive purified protein derivative ( PPD ) and/or positive interferongamma release assay . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>